Boston Scientific Co. (NYSE:BSX) Shares Sold by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. trimmed its position in Boston Scientific Co. (NYSE:BSX) by 9.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,900 shares of the medical equipment provider’s stock after selling 300 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Boston Scientific were worth $223,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sierra Summit Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth approximately $8,038,000. TD Asset Management Inc lifted its holdings in shares of Boston Scientific by 10.7% in the 4th quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after acquiring an additional 155,565 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of Boston Scientific by 225.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock worth $7,237,000 after acquiring an additional 73,219 shares during the last quarter. BDF Gestion acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $3,570,000. Finally, Precision Wealth Strategies LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth approximately $956,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BSX shares. Evercore ISI increased their price objective on shares of Boston Scientific from $78.00 to $81.00 and gave the company an “outperform” rating in a research report on Tuesday, July 2nd. Citigroup increased their price objective on shares of Boston Scientific from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Morgan Stanley increased their price objective on shares of Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. Mizuho increased their target price on shares of Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, May 15th. Finally, Truist Financial increased their target price on shares of Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $84.76.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.21 during mid-day trading on Tuesday, hitting $78.47. The stock had a trading volume of 1,120,138 shares, compared to its average volume of 6,181,194. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $79.43. The firm has a market cap of $115.12 billion, a PE ratio of 66.12, a PEG ratio of 2.49 and a beta of 0.78. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The company’s 50-day simple moving average is $76.43 and its 200-day simple moving average is $72.10.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The company had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter last year, the business earned $0.53 EPS. The business’s revenue was up 14.5% on a year-over-year basis. Sell-side analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $75.33, for a total transaction of $526,029.39. Following the completion of the transaction, the executive vice president now directly owns 45,628 shares in the company, valued at approximately $3,437,157.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $75.33, for a total transaction of $526,029.39. Following the completion of the sale, the executive vice president now directly owns 45,628 shares in the company, valued at $3,437,157.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 14,011 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $75.34, for a total transaction of $1,055,588.74. Following the completion of the sale, the executive vice president now owns 20,197 shares of the company’s stock, valued at $1,521,641.98. The disclosure for this sale can be found here. Insiders sold 34,960 shares of company stock worth $2,638,984 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.